Mineralys Therapeutics, Inc. (MLYS) Posts Phase 3 Data: BP Cut and 52% Albuminuria Drop in CKD
Mineralys Therapeutics (MLYS) reported Phase 3 data showing lorundrostat reduced systolic blood pressure and albuminuria in CKD patients. FDA review is ongoing with a PDUFA date of Dec 22, 2026.
How this was made
The 30-second read
Why it matters
The data provides a clear efficacy signal that may accelerate FDA approval and commercial rollout.
Market read
First‑report Phase 3 data is a catalyst for the stock and the renal‑therapy sector.
What to watch
Potential competition from other renal‑failure therapies and reimbursement uncertainties.
Background
Mineralys Therapeutics announced its Phase 3 Launch‑HTN trial results, highlighting blood‑pressure reduction and albuminuria improvement.
Ticker impact
Phase 3 data shows lorundrostat cuts SBP and reduces albuminuria 52% in CKD patients.
potential upside as market prices in the favorable trial data
New pivotal trial data is material for a biotech and often drives price moves.
Market effects
Strengthens the CKD therapeutic sector and may lift peer biotech valuations.
U.S. biotech market could see modest gains.
Limited to investors tracking renal‑failure drug pipelines.
Counterpoint
If FDA raises concerns about safety, the stock could face pressure despite the data.
Key entities
- companyMineralys Therapeutics, Inc.
Biotech developing lorundrostat for hypertension and CKD.
